Patient Characteristics, Treatment Patterns, and Factors of Biomarker Testing Among Patients with Advanced Non-Small Cell Lung Cancer (ANSCLC) in the US, 2012-2020

Author(s)

Yang M1, MacEwan J2, Honnold R3, McClain MR2, O'Hara R1, Liu F1, Paik P4
1EMD Serono, Rockland, MA, USA, 2Genesis Research, Hoboken, NJ, USA, 3Covera Health, New York, NY, USA, 4Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Presentation Documents

OBJECTIVES: This study describes patient characteristics, treatment patterns, and factors associated with biomarker testing in real-world US patients with advanced non-small cell lung cancer (aNSCLC).

METHODS: This retrospective cohort study of aNSCLC patients used the TEMPUS CancerLinQ oncology dataset. Patients diagnosed with stage IIIB/IV NSCLC (index date) between 1/1/2012 and 12/31/2020 and >18 years of age at index were included. Patient demographic and clinical characteristics were evaluated as potential predictors of biomarker testing (i.e. EGFR, KRAS, ALK, ROS1, BRAF, NTRK, MET, RET, or PD-L1) after aNSCLC diagnosis using logistic regression.

RESULTS: 6,877 patients met study criteria: 46.1% were female, median age (IQR) was 65.2 years (58.5–72.7), 73.1% were white, and 90.5% were diagnosed at stage IV. 41.7% (n=) patients received biomarker testing. 63.6% (n=4,377) received first-line (1L) treatment and 63.3% (n=2,771) and 24.8% (n=1,085) of those patients received 2L and 3L therapy, respectively. 1L treatment included chemotherapy (69.8%), chemotherapy + immune checkpoint inhibitor (ICI) (11.0%), ICI monotherapy (10.1%), tyrosine kinase inhibitors (7.9%), and other treatments (1.2%). Men (versus women; OR: 0.82, 95% CI: 0.74, 0.91), Black patients (versus White; OR: 0.83; 95% CI: 0.72, 0.97), patients with squamous (OR: 0.22, 95% CI: 0.19, 0.25) or unknown histology (OR: 0.53, 95% CI: 0.45, 0.61) (versus non-squamous histology), and patients with an ECOG of 2+ (OR: 0.69; 95% CI: 0.57, 0.84) or missing (OR: 0.56, 95% CI: 0.48, 0.66) (versus ECOG of 0) were less likely to undergo biomarker testing. Never smokers (versus current smokers; OR: 2.64; 95% CI: 2.05, 3.42), and patients diagnosed after 2015 (versus 2012) were more likely to undergo biomarker testing.

CONCLUSIONS: Despite the increase in targeted therapies for aNSCLC and ease of biomarker testing, many real-world aNSCLC patients were untested. Specifically, men, Black patients, current smokers, and patients with ECOG of 2+ were less likely to be tested.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

CO73

Topic

Clinical Outcomes

Topic Subcategory

Clinical Outcomes Assessment, Comparative Effectiveness or Efficacy

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×